Literature DB >> 23626635

The role of developing breast cancer in alteration of serum lipid profile.

Kamal Eldin A Abdelsalam1, Ikhlas K Hassan, Isam A Sadig.   

Abstract

AIMS: The major aim of this study is to examine the role of alterations in lipid profile in women developing breast cancer. This study was carried out between May 2009 and December 2010.
BACKGROUND: The relationship between lipids and breast cancer is undistinguished. Until now, conflicting results have been reported on the association between lipids and risk of breast cancer development in women.
MATERIALS AND METHODS: Plasma lipids (i.e., total cholesterol [TC], high-density lipoprotein [HDL], low-density lipoprotein [LDL], and triglycerides [TG] were analyzed from 60 controls and 120 untreated breast cancer patients with clinical and histopathological evidence, under aseptic conditions. Venous blood was drawn from the cases and controls and estimations of lipid profile were done utilizing the standard procedures. STATISTICAL ANALYSIS USED: Independent sample t-test to compare the mean serum levels of lipid profile and TC/HDL ratio between patients and controls.
RESULTS: A significant rise in serum total cholesterol, low-density lipoprotein cholesterol, and ratio of total cholesterol: high density lipoprotein cholesterol values, whereas high density lipoprotein cholesterol and very low density lipoprotein cholesterol were not affected significantly by the breast cancer.
CONCLUSIONS: The developing breast cancer might be considered as one of the factors in alterations in lipid profile levels.

Entities:  

Keywords:  Breast cancer; high-density lipoprotein; lipid profile total cholesterol; low-density lipoprotein; triglycerides

Year:  2012        PMID: 23626635      PMCID: PMC3634296     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


INTRODUCTION

The lipid profile---also known as lipid panel---is a group of tests that are often ordered together to determine risk of coronary heart disease.[1] A physician may ask the patient to carry out a lipid profile as part of an annual medical check or if there is specific concern about cardiovascular disease (CVD), especially coronary artery disease. They are tests that have been shown to be good indicators of whether someone is likely to have a heart attack or stroke caused by blockage of blood vessels or hardening of the arteries (atherosclerosis).[2] The lipid profile typically includes: [3 Total cholesterol High density lipoprotein cholesterol (HDL-C)-often referred to as good cholesterol Low density lipoprotein cholesterol (LDL-C)-often referred to as bad cholesterol Very low density lipoprotein cholesterol (VLDL-C) The lipid profile report may include the ratio of cholesterol to HDL.[3] This ratio is sometimes used in place of total blood cholesterol. The goal is to keep the ratio optimally at 3.5:1.[4] A lipid profile should be done after a nine- to twelve-hour fasting. If fasting is difficult to achieve, the values for total cholesterol and HDL-C may still be useful.[5] If total cholesterol is 200 mg/dl or higher or HDL-C is less than 40 mg/dl, the individual will require to have a follow-up lipoprotein profile to determine LDL-C and triglyceride levels.[6] VLDL is a calculated number and not a typical measurement. It is estimated that VLDL equals 20% of total triglyceride levels, which is why triglycerides are divided by 5 to provide an estimated VLDL level. [ 7 ] Several studies have demonstrated changes in serum lipids in cancer patients. Studies in patients with many types of cancers have demonstrated an increase in serum triglyceride concentrations with disease progression, which may also be accompanied by a decrease in serum HDL cholesterol.[8] Breast cancer remains the most common type of cancer in females in the developed countries.[9] It has been postulated that changes in the concentrations of serum lipids in breast cancer could result from increased production of tumor necrosis factor (TNFa) by activated macrophages in response to the tumor.[10] Breast cancer occurs when cells in the breast tissue divide and grow without control. Physicians divide cancer into four main stages. Most physicians use the American Joint Committee on Cancer staging system.[11]

Stage I breast cancer

The tumor is no more than 2 centimeters (cm), there are no cancer cells in the lymph nodes in the armpit, and the cancer has not spread anywhere else.

Stage II breast cancer

The lymph nodes under the arm contain cancer and the cancer has not spread and the lymph nodes under the arm contain cancer but the cancer has not spread. In the stage 2A the tumor is less than 2 cm while in the stage 2B the tumor is between 2 and 5 cm.

Stage III breast cancer

Although no tumor is seen in the breast, the lymph nodes under the arm contain cancer cells and are stuck together or to other structures, but there is no sign of cancer spread. In the stage 3A, the tumor is more than 5 cm, in stage 3 B the tumor is fixed to the skin or chest wall, the lymph nodes may or may not contain cancer cells, but there is no further spread while in stage 3C, the tumor can be any size and has spread to lymph nodes in the armpit and under the breast bone, or to nodes above or below the collarbone, but there is no further spread.

Stage IV breast cancer

The tumor can be measured any size, the lymph nodes may or may not contain cancer cells, and the cancer has spread (metastasised) to other parts of the body such as the lungs, liver or bones. The relationship between lipids and breast cancer is undistinguished. Until now, conflicting results have been reported on the association between lipids and risk of breast cancer in women. Some studies found that the dietary fat increases breast cancer risk. These studies have been strongly supported by international data collected among developed countries during the past few decades. Population aggregates with elevated lipid intake have tended to report elevated breast cancer incidence and mortality.[12] The major aim of this study is to examine the role of developing breast cancer in alterations in lipid profile in women.

MATERIALS AND METHODS

Serum was obtained from 60 normal healthy persons (control) and 120 patients with different stages of untreated breast cancer patients with clinical and histopathological evidence, from the out patients and hospital admissions admitted to the Radiation and Isotopes Center Khartoum (RICK) in period between January, 2008 and December, 2009. The patients and control groups were all females and were age matched. The sample size was calculated by using the formula: N = z2pq/d2 Were N ≡ sample size z ≡ the standard normal deviation (1.96) which corresponded to the level of 95% confidence level p ≡ proportion in target population q ≡ 1-p d ≡ degree of the accuracy desired Many factors have been previously mentioned by many authors to influencing lipid profile in patients other than these with breast cancer were excluded from this study. These factors include diabetes mellitus, thyroid disorder, pregnancy, cardiac disease, obesity, alcohol abuse, renal diseases and other factors. [ 7 ] . Fasting 10 ml venous blood was drawn and serum was separated and analyzed within 6 hours at maximum. The lipid profile tests (T-C, HDL-C, LDL-C, VLDL, and T-C: HDL ratio) were analyzed in each sample. The estimations were done using ready made enzymatic kits for cholesterol, triglyceride, and high density lipoprotein.[13] Very low density lipoprotein and low density lipoprotein results are obtained by Friedewald's equation[14] in which: VLDL = TG/5 LDL = T. Cholesterol - HDL - VLDL Obtained data were analyzed by using independent sample t-test by Statistical Packages for Social Science Software (SPSS). Statistical analysis where the value of P < 0.05 is considered as significant and P < 0.01 as highly significant.

Ethical clearance

This study was approved by the ethical committee of Radiation and Isotopes Center Khartoum (RICK) as a cross-sectional study. Informed consent was obtained from each participant.

RESULTS

The results showed that the values of T-C, LDL-C, and T-C/ HDL-C ratio were significantly increased in all the four stages of breast cancer comparing to the control group. The values of HDL-C and VLDL were not affected. Lipid profile and T-C: HDL-C ratio showed insignificant variations when comparison was carried between stages results [Table 1].
Table 1

Serum lipoproteins values during different stages of breast (mean ± SD)

Serum lipoproteins values during different stages of breast (mean ± SD) The values of lipid profile and T-C: HDL-C ratios in relation to parity in breast cancer patients were insignificantly changed when compare the results between primiparity (one birth) and multiparity (2-5 birth) [Table 2].
Table 2

Effect of parity in breast cancer patients on serum lipoproteins values (mean ± SD)

Effect of parity in breast cancer patients on serum lipoproteins values (mean ± SD) The patients with breast cancer, in this study, were classified into three age groups. The values of lipid profile and T-C: HDL-C ratios were insignificantly changed when compare the results between these 3 groups [Table 3].
Table 3

Effect of age in breast cancer patients on serum lipoproteins values (mean ± SD)

Effect of age in breast cancer patients on serum lipoproteins values (mean ± SD) The patients with breast cancer (all cancer stages) were divided as premenopaused ladies and postmenopaused ladies. The values of lipid profile and T-C: HDL-C ratios were insignificantly changed when compare the results between the two groups [Table 4].
Table 4

Serum lipoproteins values of breast cancer patients during pre and postmenopausal status (mean ± SD)

Serum lipoproteins values of breast cancer patients during pre and postmenopausal status (mean ± SD)

DISCUSSION

Getting breast cancer will undoubtedly change the patient life. Most women share a common fear: developing breast cancer. This is not an unfounded fear when considering that, except for lung cancer, breast cancer is the most common cancer found in women, accounting for one of every three diagnoses.[15] Cancerous tumors in the breast usually grow slowly. It is thought that by the time a tumor is large enough to be felt as a lump, it may have been growing for as long as 10 years. Early diagnosis is the best way to reduce the risk of dying from breast cancer.[16] In this study, as in Table 1, values of T-C, LDL-C, and T-C/ HDL-C ratio were significantly increased in all the four stages of breast cancer (P value <0.05), while the values of HDL-C and VLDL were not significantly changed. These findings are in agreement with Florenza et al.[17] and Michael et al.,[18] but disagreed with Patricia et al.[19] who found that HDL-C levels were significantly decreased, and also disagrees with Kiran et al.[20] who found that TG results (and VLDL-C levels) were significantly increased especially in stage IV patients with breast cancer. The increased T-C and LDL-C values and decreased HDL-C value increases the risk of coronary heart disease.[21] From the results and as demonstrated in Tables 2–4, all parameters (parity, age, and menopausal status respectively) showed insignificant effect on lipid profile. These findings were agreeing with those of Tornberg et al.[22]

CONCLUSION

Lipid profile and T-C: HDL-C ratios were increased significantly in breast cancer in all stages.
  17 in total

1.  Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure.

Authors:  S A Törnberg; L E Holm; J M Carstensen
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

Review 2.  Lipoproteins in relation to cancer.

Authors:  M Barclay; V P Skipski
Journal:  Prog Biochem Pharmacol       Date:  1975

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Prognostic markers in triple-negative breast cancer.

Authors:  Emad A Rakha; Maysa E El-Sayed; Andrew R Green; Andrew H S Lee; John F Robertson; Ian O Ellis
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

5.  Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects.

Authors:  A M Fiorenza; A Branchi; D Sommariva
Journal:  Int J Clin Lab Res       Date:  2000

Review 6.  Significance, detection and markers of disseminated breast cancer cells.

Authors:  Marc Lacroix
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

7.  Strategies for implementing lipid-lowering therapy: pharmacy-based approach.

Authors:  K K Birtcher; C Bowden; C M Ballantyne; M Huyen
Journal:  Am J Cardiol       Date:  2000-02-10       Impact factor: 2.778

8.  Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI.

Authors:  Patricia G Yancey; W Gray Jerome; Hong Yu; Evelyn E Griffin; Brian E Cox; Vladimir R Babaev; Sergio Fazio; MacRae F Linton
Journal:  J Lipid Res       Date:  2007-02-13       Impact factor: 5.922

9.  Alterations of serum cholesterol and serum lipoprotein in breast cancer of women.

Authors:  Kiran Hasija; Hardeep K Bagga
Journal:  Indian J Clin Biochem       Date:  2005-01

10.  Belonging to a peer support group enhance the quality of life and adherence rate in patients affected by breast cancer: A non-randomized controlled clinical trial.

Authors:  Afsaneh Malekpour Tehrani; Ziba Farajzadegan; Fariborz Mokarian Rajabi; Ahmad Reza Zamani
Journal:  J Res Med Sci       Date:  2011-05       Impact factor: 1.852

View more
  10 in total

1.  A comparitive study to evaluate the role of serum lipid levels in aetiology of carcinoma breast.

Authors:  Vipan Kumar; Amandeep Singh; D S Sidhu; K M D S Panag
Journal:  J Clin Diagn Res       Date:  2015-02-01

2.  Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients.

Authors:  Sandra Guaita-Esteruelas; Paula Saavedra-García; Alba Bosquet; Joan Borràs; Josefa Girona; Kepa Amiliano; Marta Rodríguez-Balada; Mercedes Heras; Luís Masana; Josep Gumà
Journal:  Oncologist       Date:  2017-07-12

3.  Radiotherapy improves serum fatty acids and lipid profile in breast cancer.

Authors:  Sana Shaikh; Naseem Aslam Channa; Farha Naz Talpur; Muhammad Younis; Naila Tabassum
Journal:  Lipids Health Dis       Date:  2017-05-18       Impact factor: 3.876

4.  Association between serum lipids and breast cancer risk in premenopausal women: systematic review and meta-analysis.

Authors:  Jing Wu; Xun Lei; Xianjun Pan; Xiaohua Zeng; Wei Li
Journal:  J Int Med Res       Date:  2021-11       Impact factor: 1.671

Review 5.  Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?

Authors:  Carmelita Abrahams; Nicholas J Woudberg; Sandrine Lecour
Journal:  Lipids Health Dis       Date:  2022-09-01       Impact factor: 4.315

6.  Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression.

Authors:  Catarina Rodrigues Dos Santos; Isabel Fonseca; Sérgio Dias; J C Mendes de Almeida
Journal:  BMC Cancer       Date:  2014-02-26       Impact factor: 4.430

7.  Serum Lipids and Breast Cancer Risk: A Meta-Analysis of Prospective Cohort Studies.

Authors:  Haibo Ni; Huixiang Liu; Rong Gao
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

8.  Leptin receptor Q223R polymorphism in Egyptian female patients with breast cancer.

Authors:  Mona Abo-Bakr El-Hussiny; Mohmed Ali Atwa; Waleed Elnahas Rashad; Dalia A Shaheen; Nora Marzouk Elkady
Journal:  Contemp Oncol (Pozn)       Date:  2017-03-22

9.  Association of Dyslipidemia, Increased Insulin Resistance, and Serum CA 15-3 with Increased Risk of Breast Cancer in Urban Areas of North and Central India.

Authors:  Poonam Kachhawa; Kamal Kachhawa; Divya Agrawal; Vivek Sinha; Purnima Dey Sarkar; Sanjay Kumar
Journal:  J Midlife Health       Date:  2018 Apr-Jun

10.  Could Anthropometric and Lipid Parameters Reflect Susceptibility to Breast Cancer? Comparison of Newly Diagnosed Breast Cancer and Apparently Healthy Women

Authors:  H M K Akalanka; S Ekanayake; K Samarasinghe
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.